{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-047748","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.247729+00:00","generated_at":"2026-05-15T03:45:49.250862+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis","bullets":["Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.","Rezafungin showed favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions.","Target supplemental NDA submission to FDA in 2H26 based on ReSPECT results.","CorMedix estimates US prophylaxis market opportunity for REZZAYO exceeds $2 billion.","Mundipharma sponsored the trial; holds ex-US rights; Melinta (CorMedix sub) distributes in US."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-047748","json":"https://secwatch.observer/filing/0001213900-26-047748.json","markdown":"https://secwatch.observer/filing/0001213900-26-047748.md","text":"https://secwatch.observer/filing/0001213900-26-047748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/0001213900-26-047748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/ea0287640-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:45:49.250862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}